Company
Global medical technology company
Every investor coverage indicates participated in a round Medtronic raised.
Companies Medtronic acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Medtronic. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
ANDHealth's blog interviews Australis Scientific's founder about its wearable therapy for bladder conditions, its years in ANDHealth programs, and plans to scale the device at home and abroad.
Profile of a Melbourne medtech firm making lifelike artificial organs that let surgeons rehearse robotic procedures, noting its 2023 capital raise, rapid growth, and leadership training through a Victorian scaleup program.
Cardiac device maker EBR Systems has won US regulator clearance for its leadless heart-failure therapy, clearing the way for staged commercial release later in 2025 and broader distribution in 2026.
EBR Systems has won US regulatory approval for its WiSE implant, the first leadless device for a form of cardiac resynchronization therapy, which the CEO frames as the end of a 22-year development phase.
Australian wearable-sensor maker dorsaVi has built a beta spinal movement sensor with Medtronic after eighteen months of collaboration, and the two firms have extended their partnership toward commercialisation.
Medical device maker AirXpanders appoints US industry veteran Frank Grillo as chief executive, succeeding interim leader Scott Murcray, with co-founder Barry Cheskin welcoming the hire ahead of Grillo fronting July's investor call.
US-based medical device maker AirXpanders, listed on the ASX, proposes adding Liz Hammack to its board as co-founder Teddy Shalon departs and fellow director Dennis Condon faces re-election at its May annual meeting.
Sunshine Heart says the US regulator has conditionally cleared its first American trial of the C-Pulse heart assist device, with about twenty patients to enrol across six US hospitals from late 2008.
Two American heart failure specialists have agreed to serve as co-principal investigators for Sunshine Heart's C-Pulse feasibility trial, which the company says adds credibility as it prepares a wider US study in 2007.
Axion founder Daniel First announces a $37 million Series B with Salesforce Ventures leading, lifting total raised to $64 million, and describes the company's AI platform for resolving product quality issues in manufacturing.
Also axion.com